JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Verel, I.
Right arrow Articles by van Dongen, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verel, I.
Right arrow Articles by van Dongen, G. A.
Journal of Nuclear Medicine Vol. 46 No. 1 (Suppl) 164S-171S
© 2005 by Society of Nuclear Medicine

The Promise of Immuno-PET in Radioimmunotherapy

Iris Verel, PhD1, Gerard W.M. Visser, PhD2 and Guus A. van Dongen, MS, PhD1

1 Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam, The Netherlands
2 Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, The Netherlands

Immuno-PET as a quantitative imaging procedure before or concomitant with radioimmunotherapy is an attractive option to improve confirmation of tumor targeting and especially assessment of radiation dose delivery to both tumor and normal tissues. General information about PET, PET systems, and quantification is provided in this review. The requirements for an appropriate positron emitter and characteristics of the most attractive candidate emitters for immuno-PET are discussed. An overview of preclinical and clinical immuno-PET studies reported in the literature is provided.

Key Words: immuno-PET • radioimmunotherapy • monoclonal antibodies • positron emitters • oncology




This article has been cited by other articles:


Home page
 JNMHome page
Z. Cheng, O. P. De Jesus, M. Namavari, A. De, J. Levi, J. M. Webster, R. Zhang, B. Lee, F. A. Syud, and S. S. Gambhir
Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with Site-Specific 18F-Labeled Protein Scaffold Molecules
J. Nucl. Med., May 1, 2008; 49(5): 804 - 813.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
G. A.M.S. van Dongen, G. W.M. Visser, M. N. Lub-de Hooge, E. G. de Vries, and L. R. Perk
Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications
Oncologist, December 1, 2007; 12(12): 1379 - 1389.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. E. Shively
18F Labeling for Immuno-PET: Where Speed and Contrast Meet
J. Nucl. Med., February 1, 2007; 48(2): 170 - 172.
[Full Text] [PDF]

Home page
 JNMHome page
L. R. Perk, G. W.M. Visser, M. J.W.D. Vosjan, M. Stigter-van Walsum, B. M. Tijink, C. R. Leemans, and G. A.M.S. van Dongen
89Zr as a PET Surrogate Radioisotope for Scouting Biodistribution of the Therapeutic Radiometals 90Y and 177Lu in Tumor-Bearing Nude Mice After Coupling to the Internalizing Antibody Cetuximab
J. Nucl. Med., November 1, 2005; 46(11): 1898 - 1906.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.